Grant: Ca. Gr.: Biomedical Res. for HIV/AIDS/STBBI -Next-gen. therapeutic interventions
University of Manitoba
$200,000.00
Evaluation of IFN-lambda as a novel antiviral therapeutic for genital HPV and HSV-2 infection in vivo
EF 2024-25
Résumé
Human papillomavirus (HPV) and HSV-2 are both sexually transmitted blood borne infections (STBBIs) that leads to poor long-term health outcomes in infected individuals. There are currently no cures available for either viral infections, underscoring the need for potent, broadly acting therapies against these viral STBBIs. In this proposal, we will test whether interferon-lambda, a protein naturally produced by immune cells to help eliminate viruses, can be formulated as a novel therapeutic agent against genital HPV and HSV-2 infection. The goal is to develop long-acting therapeutic interventions designed to promote viral clearance and protection the genital tract from subsequent viral infections.
Programme
Ca. Gr.: Biomedical Res. for HIV/AIDS/STBBI -Next-gen. therapeutic interventions
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
521689
Name
Murooka Thomas T
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant : Biomedical Research for HIV/AIDS and STBBI
Projecttitle
Evaluation of IFN-lambda as a novel antiviral therapeutic for genital HPV and HSV-2 infection in vivo
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$200,000
Cihrequipment2
$0
Programname2
Ca. Gr.: Biomedical Res. for HIV/AIDS/STBBI -Next-gen. therapeutic interventions
Keyworddelim
Female Genital Tract; Herpes Simplex Virus (Hsv); Human Papillomavirus (Hpv); Immune Activation; Inflammation; Innate Immunity; Interferon-Lambda; Mouse Models Of Infection; Vaginal Epithelial Barrier; Virus Replication
Abstract
Human papillomavirus (HPV) and HSV-2 are both sexually transmitted blood borne infections (STBBIs) that leads to poor long-term health outcomes in infected individuals. There are currently no cures available for either viral infections, underscoring the need for potent, broadly acting therapies against these viral STBBIs. In this proposal, we will test whether interferon-lambda, a protein naturally produced by immune cells to help eliminate viruses, can be formulated as a novel therapeutic agent against genital HPV and HSV-2 infection. The goal is to develop long-acting therapeutic interventions designed to promote viral clearance and protection the genital tract from subsequent viral infections.
Competitiondate
202410
Approvedterm2
1 yr 0 mth
Pinamesdelim
Murooka, Thomas T; Ashkar, Ali A; Santer, Deanna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $200,000~ $0~
